Why Autolus Therapeutics plc’s (AUTL) Stock Is Up 6.99%
As of Wednesday, August 19, Autolus Therapeutics plc’s AUTL share price has surged by 6.99%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Commentary & Analysis
Why Autolus Therapeutics plc’s (AUTL) Stock Is Up 6.28%
As of Monday, August 17, Autolus Therapeutics plc’s AUTL share price has surged by 6.28%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Autolus Therapeutics plc’s (AUTL) Stock Is Down 5.63%
As of Friday, August 14, Autolus Therapeutics plc’s AUTL share price has dipped by 5.63%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Autolus Therapeutics plc’s (AUTL) Stock Is Up 5.19%
As of Thursday, August 13, Autolus Therapeutics plc’s AUTL share price has surged by 5.19%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Autolus Therapeutics plc’s (AUTL) Stock Is Down 6.44%
As of Wednesday, August 12, Autolus Therapeutics plc’s AUTL share price has dipped by 6.44%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | AUTL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $503.0 | $262.9 | 37% |
|
| Shares Out (Mil) | 266.2 | 54.4 | 81% |
|
| Institutional Ownership | 74.8% | 92.9% | 45% |
|
| Float (Mil) | 102.9 | 41.5 | 61% |
|
| Beta | 2.02 | 0.94 | 92% |
|
| Avg Daily Volume (000s) | 1,733 | 496 | 81% |
|
| Price Change (52-week) |
37.0% | 54.5% | 77% |
|
| Growth | AUTL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 113.5% | 14.1% | 99% |
|
| Net Income (5yr) | (15.1%) | (10.1%) | 25% |
|
| EPS (5yr) | 17.1% | 15.8% | 62 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 16.2% | (15.6%) | 75% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | na | 8 | |
| Current EPS | ($0.162) | na | ($0.792) | |
| Month Ago EPS | ($0.173) | na | ($0.790) | |
| # Rev Up | 1 | na | 0 | |
| # Rev Down | 0 | na | 1 | |
| Three Months Ago EPS | ($0.214) | na | ($0.900) | |
| Year/Year Chg | 10.2% | na | na | |
| Financials | AUTL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $117 | $37 | 27% |
|
| Net Income (TTM) (Mil) | ($280) | ($43) | 5% |
|
| EPS (TTM) | ($1.053) | ($1.500) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($226) | ($31) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $48 | $2 | 69% |
|
| Long-Term Debt (Q1) (Mil) | $349 | $4 | 55% |
|
| Enterprise Value (Q1) (Mil) | $738 | $179 | 37% |
|
| Valuation | AUTL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.75 | 2.56 | 85% |
|
| P/E | na | 18.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | AUTL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (74.6%) | 68.2% | 2% |
|
| Net Margin | (238.7%) | (73.0%) | 4% |
|
| ROA | (46.1%) | (47.9%) | 12% |
|
| ROE | (133.0%) | (55.0%) | 7% |
|
| Liabilities to Assets | 84.8% | 29.4% | 78% |
|
| F-Score | 1 | 2 | 1% |
|
Autolus Therapeutics plc did not pass any screens on 9/15/2026.
